2 min read
Mexico is a significant pharmaceutical market with evolving Regulatory requirements governed by the Federal Commission for Protection against Health Risks (Cofepris). However, foreign pharmaceutical companies entering this market face Regulatory hurdles that can impact market entry and growth.
Here are six key Regulatory challenges in Mexico's pharmaceutical landscape and strategies to overcome them:
1. Market Access and Financing
Innovative medicines often face challenges in gaining inclusion in the national formulary, which determines the reimbursement of medicines by public institutions.
How to Overcome It:
- Engage with local authorities to understand the national formulary's evaluation criteria.
- Develop a market access strategy that aligns with managed entry agreements and value-based pricing models.
- Explore partnerships with stakeholders to navigate reimbursement complexities.
2. Regulatory Efficiency
The approval process for new medicines in Mexico is slow, with delays in obtaining health registration from Cofepris. The backlog of unfinished Regulatory procedures further extends approval timelines.
How to Overcome It:
- Establish early communication with Cofepris to ensure compliance with submission requirements.
- Work with Regulatory experts to streamline documentation and avoid delays.
3. Intellectual Property Protections
There is uncertainty surrounding biopharmaceutical intellectual property (IP) protection, particularly under re-negotiated trade agreements. Regulatory Data Protection (RDP) and patent linkage are inconsistently applied.
How to Overcome It:
- Conduct a thorough review of Mexico’s IP framework before market entry.
- Register patents in the Instituto Mexicano de la Propiedad Intelectual (IMPI)
and RDP in Mexico to ensure protection against potential infringements.
- Engage legal experts to monitor and navigate evolving IP regulations.
4. Transparency and Fairness in Procurement
Foreign pharmaceutical companies often perceive a lack of transparency in Mexico’s public procurement processes, with preferential treatment given to local companies. High import taxes further challenge market competitiveness.
How to Overcome It:
- Stay informed about Regulatory changes impacting procurement procedures.
- Participate in international tenders and follow transparent bidding processes.
- Consider local partnerships to enhance competitive positioning in public tenders.
5. Local Partnerships and Investment
Foreign companies without a local presence may struggle with Regulatory navigation, supply chain complexities, and market integration.
How to Overcome It:
- Establish partnerships with local manufacturers or distributors to streamline Regulatory compliance.
- Explore investment opportunities in local manufacturing to benefit from preferential treatment in public tenders.
- Build strong networks with key stakeholders to facilitate market entry.
6. Pharmacovigilance and Compliance
Mexico places strong emphasis on post-market surveillance and pharmacovigilance, requiring companies to monitor, track, and report adverse events. Non-compliance can lead to penalties and market restrictions.
How to Overcome It:
- Implement a robust pharmacovigilance system that meets Cofepris requirements.
- Ensure adherence to Good Manufacturing Practices (GMP) and local Regulatory standards.
- Regularly update compliance frameworks to align with evolving regulations.
By proactively addressing these challenges with strategic Regulatory planning, foreign pharmaceutical companies can successfully enter and expand within the Mexican market.
Need assistance in navigating Mexico’s Regulatory landscape? Contact us today!
